Innoviva Free Cash Flow 2012-2026 | INVA
Innoviva free cash flow from 2012 to 2026. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Innoviva Annual Free Cash Flow | |
|---|---|
| 2025 | |
| 2024 | 188.52 |
| 2023 | 140.65 |
| 2022 | 201.66 |
| 2021 | 363.81 |
| 2020 | 313.10 |
| 2019 | 257.45 |
| 2018 | 223.53 |
| 2017 | 141.75 |
| 2016 | 60.71 |
| 2015 | 10.12 |
| 2014 | -266.41 |
| 2013 | -217.34 |
| 2012 | -130.10 |
| 2011 | -91.97 |
| Innoviva Quarterly Free Cash Flow | |
|---|---|
| 2026-03-31 | |
| 2025-09-30 | 141.30 |
| 2025-06-30 | 92.69 |
| 2025-03-31 | 48.62 |
| 2024-12-31 | 188.52 |
| 2024-09-30 | 129.28 |
| 2024-06-30 | 80.86 |
| 2024-03-31 | 37.15 |
| 2023-12-31 | 140.65 |
| 2023-09-30 | 107.55 |
| 2023-06-30 | 63.83 |
| 2023-03-31 | 25.65 |
| 2022-12-31 | 201.66 |
| 2022-09-30 | 192.79 |
| 2022-06-30 | 177.12 |
| 2022-03-31 | 98.09 |
| 2021-12-31 | 363.81 |
| 2021-09-30 | 265.43 |
| 2021-06-30 | 168.72 |
| 2021-03-31 | 84.11 |
| 2020-12-31 | 313.10 |
| 2020-09-30 | 227.82 |
| 2020-06-30 | 153.26 |
| 2020-03-31 | 73.47 |
| 2019-12-31 | 257.45 |
| 2019-09-30 | 190.55 |
| 2019-06-30 | 133.15 |
| 2019-03-31 | 76.66 |
| 2018-12-31 | 223.53 |
| 2018-09-30 | 161.75 |
| 2018-06-30 | 101.64 |
| 2018-03-31 | 49.91 |
| 2017-12-31 | 141.75 |
| 2017-09-30 | 93.89 |
| 2017-06-30 | 50.40 |
| 2017-03-31 | 27.76 |
| 2016-12-31 | 60.71 |
| 2016-09-30 | 39.65 |
| 2016-06-30 | 19.70 |
| 2016-03-31 | 7.25 |
| 2015-12-31 | 10.12 |
| 2015-09-30 | 3.21 |
| 2015-06-30 | 0.55 |
| 2015-03-31 | -1.62 |
| 2014-12-31 | -266.41 |
| 2014-09-30 | -126.67 |
| 2014-06-30 | -105.60 |
| 2014-03-31 | -107.26 |
| 2013-12-31 | -217.34 |
| 2013-09-30 | -91.30 |
| 2013-06-30 | -49.75 |
| 2013-03-31 | -32.37 |
| 2012-12-31 | -130.10 |
| 2012-09-30 | -105.59 |
| 2012-06-30 | -77.46 |
| 2012-03-31 | -42.43 |
| 2011-12-31 | -91.97 |
| 2011-09-30 | -65.71 |
| 2011-06-30 | -46.41 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |